Evaluate Adherence to Treatment With Glucophage Sachets Versus Tablets in Diabetes Type 2 Patients Previously Treated With Metformin Tablets
NCT ID: NCT01510522
Last Updated: 2014-02-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
PHASE4
INTERVENTIONAL
2012-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
To Compare the Similarity of a Combination Dapagliflozin/Metformin Tablet With the Two Drugs Administered Separately
NCT01535677
Bioequivalence Study of Saxagliptin and Glucophage Combination Formulations in Healthy Subjects (A)
NCT00899470
Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus on Background of Metformin
NCT02926950
A Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.
NCT00423501
Efficacy and Safety of Metformin Glycinate Compared to Metformin Hydrochloride on the Progression of Type 2 Diabetes
NCT04943692
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Glucophage sachets
Patients receive Glucophage sachets, the powder formulation for oral solution in sachets.
Glucophage
Glucophage Powder for oral solution in sachets (metformin hydrochloride in 850mg strengths) Dosing schedule: \> 1.700mg/day for 6 month
Glucophage tablets
Patients received Glucophage tablets.
Glucophage
Glucophage tablets (metformin hydrochloride in 850mg strengths)
Dosing schedule: \> 1.700mg/day for 6 month
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Glucophage
Glucophage Powder for oral solution in sachets (metformin hydrochloride in 850mg strengths) Dosing schedule: \> 1.700mg/day for 6 month
Glucophage
Glucophage tablets (metformin hydrochloride in 850mg strengths)
Dosing schedule: \> 1.700mg/day for 6 month
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* On treatment with metformin tablets
* Patients with at least 2 treated co-morbidities
* Established dose of Metformin \> 1.700 mg/day
* Age \> 18 years old
* Given informed consent
Exclusion Criteria
* According to Summary of Product Characteristics (SmPC)
* Participating in another clinical trial 30 days prior to randomization
* Any other illness or medical or psychiatric condition, severe and uncontrolled that could interfere in the patient's participation or in the assessment of the study results
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Merck, S.L., Spain
INDUSTRY
Merck KGaA, Darmstadt, Germany
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Responsible
Role: STUDY_DIRECTOR
Merck, S.L., Spain
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2011-002508-34
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
EMR200084-508
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.